Attention Deficit Hyperactivity Disorder (ADHD) clinical trials at UCSF
1 in progress, 0 open to new patients

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Sorry, not currently recruiting here

To evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD). Subjects will be enrolled into this study from antecedent study SPD489-211 (NCT02402166) or SPD489-347.

San Francisco, California and other locations